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The drug transporter ABCB1 c.3435C>T 
SNP influences artemether–lumefantrine 
treatment outcome
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Abstract 
Malaria treatment performance is potentially influenced by pharmacogenetic factors. This study reports an association 
study between the ABCB1 c.3435C>T, CYP3A4*1B (g.-392A>G), CYP3A5*3 (g.6986A>G) SNPs and artemether + lume-
fantrine treatment outcome in 103 uncomplicated malaria patients from Angola. No significant associations with 
the CYP3A4*1B and CYP3A5*3 were observed, while a significant predominance of the ABCB1 c.3435CC genotype was 
found among the recurrent infection-free patients (p < 0.01), suggesting a role for this transporter in AL inter-individ-
ual performance.
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Background
Artemisinin combination therapy (ACT) has contributed 
to the remarkable decline by 48% in the malaria mortal-
ity rate between 2000 and 2015 [1]. The disease remains 
a major public health challenge, causing over 400,000 
deaths annually, partly due to underperforming treat-
ments. The success of malaria treatment depends on 
many factors, not least inter-individual pharmacokinetic 
differences, which are potentially influenced by patient 
pharmacogenetic background [2].
Artemether–lumefantrine (AL) is the most adopted 
antimalarial by national malaria control programs world-
wide. In Angola, it represents the first-line treatment of 
choice for uncomplicated malaria.
Upon AL oral administration, artemether shows an 
elimination half-life of 1–3  h, CYP3A4 being the main 
enzyme involved in its conversion towards the (also 
active) dihydroartemisinin (DHA) metabolite [3]. Both 
artemether and DHA act rapidly to clear malaria para-
sites from circulation, reducing asexual parasite mass [4]. 
The lumefantrine partner has a half-life of 3–6 days and 
is responsible for the elimination of parasites remaining 
from the artemisinin ‘first impact’ action, while prevent-
ing recurrent malaria parasitaemia [5]. Only <10% of the 
absorbed LUM is biotransformed towards the active des-
butyl-benflumetol (DBB) metabolite, mainly by CYP3A 
enzymes [6].
Both lumefantrine and DHA are essentially eliminated 
through the bile. In the apical biliocanalicular membrane 
of the hepatocyte, the ABCB1 (MDR1/Pgp) ATP-binding 
cassette (ABC) transporter is a major biliary efflux pump, 
particularly for lipophilic substrates, as lumefantrine [7, 
8]. Significant inter-individual variation in drug expo-
sure is known for both artemisinin and lumefantrine, 
suggesting the potential importance of CYP3A4 and 
ABCB1 pharmacogenetic characteristics influencing AL 
performance.
A previous attempt to correlate lumefantrine pharma-
cokinetic (PK) parameters with CYP3A4 and ABCB1 tag 
SNPs, particularly the promoter located g.-392A>G in the 
former (CYP3A4*1B) and the synonymous c.3435C>T in 
the latter, did not yield significant associations [9], hav-
ing prompted the natural conclusion that such variation 
had a negligible effect [9]. Possible positive associations 
were anyway recently suggested for ABCB1 c.3435C>T 
with altered LUM exposure among HIV positive subjects 
under Efavirenz based therapy.
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In the present work, we hypothesized that small phar-
macokinetic differences might have observable pharma-
codynamic consequences, the parasite reaction being 
a more sensitive parameter of the individual pharma-
cogenetic influence. Parasite clearance on day 3 post-
treatment, recurrent infection prevalence and the 28-day 
cure rate endpoint of adequate clinical and parasito-
logic response (ACPR) were herein used as parameters 
to assess the effect of the patient pharmacogenetic sta-
tus on AL in vivo anti-parasite performance. To test this 




One-hundred and three unrelated patients with micros-
copy confirmed (1000–100,000 asexual parasites/µL) 
uncomplicated Plasmodium falciparum malaria involved 
in an AL  (Coartem®, Novartis AG, Basel) efficacy trial 
in the Luanda region, Angola, conducted during the 
2011–2013 period [10]. Briefly, upon informed written 
consent by the participant or their guardians, patients 
were treated with weight-adjusted, six-dose AL in 3 days, 
in accordance with national guidelines [11, 12]. Clinical 
assessment was performed at  D2,  D3,  D7,  D14,  D21 and 
 D28. At each time-point, thick blood films were examined 
for the presence of parasites and a capillary blood sample 
obtained for PCR analysis.
Ethical approval was obtained from the Angolan 
National Public Health Institute/Ministry of Health Eth-
ics Committee. All procedures followed the latest version 
of the Declaration of Helsinki.
Molecular genotyping
Capillary blood sample were collected on filter paper 
 (FTA® Classic Card, Whatman). DNA extraction was done 
by phenol–chloroform methods. The ABCB1 c.3435C>T, 
CYP3A4  g.-392C>G and CYP3A5  g.6986A>G SNPs were 
analysed by established PCR–RFLP protocols [13]. Pres-
ence of parasitaemia was further tested through the 
pfmsp2 PCR amplification of all samples at all time spots 
[10]. Allele frequencies of the analysed SNPs were com-
pared between groups of patients in accordance with two 
different treatment outcome phenotypes: (a) pfmsp2 posi-
tive PCR by  D3, informative concerning the artemisinin 
partner performance, in accordance with WHO guide-
lines; and, (b) pfmsp2 positive PCR during the 28-day fol-
low up (lumefantrine prophylactic effect). The number of 
clinical failure events (PCR-corrected recrudescence) was 
too small to warrant their specific analysis. All recrudes-
cences were included in the general recurrence group.
Genotyping data for the parasite pfmdr1N86Y SNP, 
a well-established factor in parasite in  vivo response to 
AL [14, 15], was available through previously performed 
PCR–RFLP methods [10].
Statistical analysis
Data on SNPs were analysed using IBM SPSS version 
23. Chi square (χ2) test and Z statistics were used to 
determine significant differences between proportions 
(Graphpad  Prism® 7, Graphpad Software Inc, La Jolla, 
CA, USA). Five individual associations were herein 
tested: recurrence vs CYP3A4*1B allele status, recur-
rence vs ABCB1 c3435C>T SNP status, recurrence vs 
CYP3A5*3 SNP status,  D3 positivity vs CYP3A4*1B SNP 
status, and  D3 positivity vs ABCB1 c.3435C>T SNP sta-
tus). Accordingly, a Bonferroni-corrected significance 
threshold at p < 0.01 was considered for these tests. Mul-
tivariate Log-linear analysis was performed in order to 
specifically investigate associations of key three categori-
cal variables: (a) D28 follow-up outcome (recurrence), 
(b) ABCB1/MDR1 c.3435C>T genotype, and (c) pfmdr1 
N86Y status of the initial infection. The multiple testing 
was Benjamini–Hochberg corrected, assuming a 10% 
false discovery rate (q).
Results
The 28-day PCR-corrected cure rate was 91.3%. On  D3, 
46.6% (n = 48) had positive PCR. During the 28-day fol-
low up, 29/103 patients experienced recurrent parasi-
taemia, as detected through PCR. Ninety-eight patients 
were successfully analysed for the CYP3A4 -392A>G SNP. 
The genotype frequency in this Angolan population was 
0.112 (0.060–0.196, 11/98) for the wild type (g.-392AA), 
0.541 (0.438–0.641, 53/98) minor allele homozygous 
(g.-392GG) and 0.347 (0.438–0.641, 34/98) for the het-
erozygous (g.-392AG). The population was found in 
Hardy–Weinberg equilibrium for this locus (p > 0.05).
The patient CYP3A4*1B genotype was not found to be 
significantly associated with either D3 parasite positiv-
ity (χ2 = 5.493, df = 1, p = 0.019) (Table 1) or treatment 
outcome upon the 28-day follow up (χ2 = 2.378, df = 1, 
p = 0.123) (Table 2).
Concerning the ABCB1 c.3435C>T SNP, 101 patients 
were successfully tested. Genotype frequencies were 
0.762 (0.667–0.841, 77/101) for the wild type (c.3435CC), 
0.079 (0.035–0.150, 8/101) for the minor allele homozy-
gous (c.3435TT) and 0.158, (0.093–0.244, 16/101) for the 
heterozygous (c.3435CT). The population was found in 
Hardy–Weinberg equilibrium for this locus (p > 0.05).
The c.3435C>T SNP was also not significantly asso-
ciated with the  D3 parasite PCR positivity (χ2  =  0.883, 
df = 1, p = 0.347) (Table 1). On the other hand, c.3435TT 
genotypes were found to be significantly more frequent 
among patients experiencing recurrent events during fol-
low-up (χ2 = 6.9693, df = 1, p = 0.008) (Table 3, Fig. 1). 
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These changes were further reflected on a significant 
increase in recurrence risk (OR  =  10.59, 1.96–57.30, 
z-score = 2.739, p = 0.006) in this subgroup.
During the completion of the present work, a new 
report has suggested CYP3A5 as a contributor to lume-
fantrine metabolism [16]. Following this lead, we have 
successfully analyzed CYP3A5*3 (c.6986A>G) in 84 sam-
ples, as this is the allele is the most investigated as having 
a robust deleterious effect in the expression of the gene 
[17]. Genotype frequencies were 0.750 (0.644–0.838, 
63/84) for the wild type (c.6986AA), 0.048, (0.013–
0.117, 4/84) for the heterozygous (c.6986AG) and 0.202 
(0.123–0.304, 17/84) for the minor allele homozygous 
(c.6986GG). The sample population was found in Hardy–
Weinberg equilibrium for this locus (p > 0.05).
As with CYP3A4*1B, no significant association was 
observed between the patient status for carrying a 
CYP3A5*3 alleles and the parasitological outcome dur-
ing the 28 day follow up (χ2 = 0.932, df = 1, p = 0.335)
(Table 2).
Due to the size limitations of the study, multivari-
ate analysis was limited to variables expected to interact 
concerning the clinical outcome under focus (D28 follow 
up positivity), namely the ABCB1 c3435C>T status and 
the pfmdr1 N86Y status. A subset of 92 cases was availa-
ble with complete data for these three variables (Table 4).
Upon the assumption of a false discovery rate of (q) of 
10% for Benjamini–Hochberg multiple test correction, 
only two associations stood out as near the threshold of 
significance: the overall interaction between the three 
analysed variables  (G2 = 10.84, df = 4, p = 0.0284 vs p 
(corrected) = 0.0286), and the association between recur-
rence during follow-up and the ABCB1 c3435C>T status 
Table 1 CYP3A4-392A>G and ABCB1 3435C>T genotype frequencies and  D3 PCR positivity (IC95%)
NO significant associations were
D3 positive positive PCR by day 3; D3 negative negative PCR by day 3
Gene/SNP Genotype frequencies (IC 95%)
D3 positive D3 negative


























Table 2 CYP3A4-392A>G and ABCB1 3435C>T genotype frequencies and risk of recurrency during the 28-day follow-up 
(IC95%)
* Significant (p < 0.01)
Recurrence-free group without positive PCR during the follow-up days
Recurrence group with positive PCR during the follow-up days
Gene/SNP Genotype frequencies (IC 95%)
Recurrence-free group Recurrence group







































Table 3 Analysis of  the association between  ABCB1 
c.3435C>T patient status and  treatment outcome 
(χ2 = 6.9693, df = 1, p = 0.008)
ABCB1 c3435C>T Recurrence status Total
Positive ACPR
CC 17 60 77
CT + TT Total 12 12 24
29 72 101
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 (G2 = 8.36, df = 2, p = 0.0146 vs p (corrected) = 0.0143), 
after filtering the effect of the presence/absence of the 
pfmdr1 N86 allele (Table  4). This analysis further sug-
gests the importance of the ABCB1 c3435C>T SNP, albeit 
the limited number of samples available recommends 
caution in the interpretation of the results.
Discussion
The present work focused on finding links between 
patient CYP3A and ABCB1 pharmacogenetics and AL 
pharmacodynamics in  vivo endpoints.  D3 positivity was 
not significantly associated with the patient CYP3A4*1B 
status (Table  1), an observation that can be simply 
explained by the fact that DHA-the main artemether 
CYP3A4 metabolite-is also highly active against P. falci-
parum parasites. Pharmacogenetic driven variable rates 
of artemether to DHA bioconversion are likely not to be 
readily visible in terms of the artemisinin effect on the 
infection. As for the ABCB1 c.3435C>T, the negative 
observations possibly result from the specific capacity 
of this transporter to efflux more lypophilic compounds 
then the final phase II glucuronidated DHA extracted 
from the liver.
The CYP3A4*1B and CYP3A4*3 status were not seen 
to influence the risk of malaria recurrence. The AL post-
treatment protective effect is essentially related with 
the action of lumefantrine, the long half-life partner. In 
regular conditions, it is expected that the large majority 
of lumefantrine is eliminated unchanged [18], a result 
supported by the previously observed modest effect of 
ketoconazole in interaction studies [6]. This means that 
any role of CYP3A4 and/or CYP3A5 will be limited to 
variations in this remain biotransformed fraction, which 
expected small size might have precluded its detection 
during the present works. One cannot nevertheless rule 
out the possibility that small changes in the concentra-
tions of the resulting DBB metabolite might influence the 
treatment, in particular because of its higher anti-parasitic 
potency, as previously suggested [19]. Also, it is likely that 
scenarios of long-term CYP3A induction might increase 
the fraction of LUM metabolism-as potentially observed 
among patients under Efavirenz therapy [20]-and as such 
the role of this cytochrome P450s on lumefantrine elimi-
nation. Nevertheless, inside its size limitations and in this 
specific population, our study suggests a likely minor con-
tribution of the CYP3A4*1B and CYP3A5*3 SNPs in mod-
ulating AL post-treatment prophylactic action.
A significant increase in the frequency of the ABCB1 
c.3435TT genotype was found among patients suffering 
recurrent infections during the 28-day follow up, sug-
gesting a role of the encoded P-glycoprotein. The synony-
mous c.3435C>T polymorphism has been proposed to be 
linked with altered rates of protein synthesis, leading to 
proteins that albeit having the same primary sequence, 
emerge from the process of translation with differ-
ent tertiary conformations [21]. The functional effect 
of such changes in the P-glycoprotein seems to depend 
on the drug under consideration. In the present stud-
ies, a substantial predominance was found of the ABCB1 
c.3435CC genotype among the recurrence-free patients, 
signalling an increased lumefantrine exposure associated 
with this genotype, which better shielded the recovering 
patients from new infections.
A shortcoming of the present study is the unavailability 
of pharmacokinetic data, namely D7 LUM levels, in order 
to have a complete pharmacokinetic/pharmacogenetic 
picture. Nevertheless, it is interesting to note that the 
present results are in agreement with recent data from 
Maganda et  al. [20], where the ABCB1 c.3435TT geno-
type, was suggested to be associated with a significantly 
decreased D7 lumefantrine levels among patients under-
going malaria treatment with AL. Such an effect in drug 
exposure can explain the increase risk of these patients 
towards recurrent infection.
Fig. 1 ABCB1/MDR1 C3435T ACPR vs recurrence experiencing group. 
CC wild type genotype, CT heterozygous genotype, TT mutant 
genotype




Pfmdr1N86Y Recurrence status Total
Positive (A1) ACPR (A2)
CC (B1) 86 N pure (C1) 8 41 49
86 N/Y + 86Y 
(C2)
9 11 20
CT + TT (B2) 86 N pure (C1) 9 8 17
86 N/Y + 86Y 
(C2)
2 4 6
Total 11 12 92
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These data suggest lumefantrine as part of the group of 
ABCB1 substrates where this genotype is associated with 
increased drug exposure, probably due to a less efficient 
efflux. Other examples include tacrolimus [22, 23], silibinin 
[24], amlodipine [25], or in some studies, digoxine [26].
Conclusion
By exploring potential pharmacodynamics/pharmaco-
genetic associations in anti-malarial therapy, this report 
shows a non-negligible influence of the host ABCB1 
c.3435C>T SNP in the performance of artemether–lume-
fantrine. The present observations join other recent 
reports pointing for the importance drug transporter 
pharmacogenetics in ACT pharmacokinetics and phar-
macodynamics [20, 27].
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